Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.56%
1,104.24
-6.23
-0.56%
—1,110.471,107.751,108.741,093.81——
SIXC
Communications
SIXC
Communications
SIXC
+0.01%
604.16
+0.090
+0.01%
—604.07604.07605.23600.91——
SIXE
Energy
SIXE
Energy
SIXE
+0.91%
1,212.47
+10.98
+0.91%
—1,201.491,205.921,214.621,201.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.72%
1,752.53
-12.77
-0.72%
—1,765.301,764.031,764.031,736.40——
SIXM
Financials
SIXM
Financials
SIXM
+0.81%
635.52
+5.10
+0.81%
—630.42630.34636.27626.03——
SIXR
Staples
SIXR
Staples
SIXR
+1.59%
854.81
+13.36
+1.59%
—841.45843.60858.11840.11——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.05%
218.73
-0.10
-0.05%
—218.83218.83219.21217.33——
SIXT
Technology
SIXT
Technology
SIXT
-2.73%
3,484.33
-97.90
-2.73%
—3,582.233,550.603,562.623,447.78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.16%
912.43
-1.46
-0.16%
—913.89912.75914.26906.67——
SIXV
Health care
SIXV
Health care
SIXV
+2.35%
1,478.23
+33.90
+2.35%
—1,444.331,446.871,480.741,446.30——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.20%
2,383.93
-29.03
-1.20%
—2,412.962,403.992,411.412,373.90——
EMCURE:NSE
Emcure Pharmaceuticals Ltd
₹1,657.00
-1.25%
(-21.00) 1D
May 12, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
₹1,679.90
High
₹1,705.00
Low
₹1,650.20
Mkt. cap
314.55B
Avg. vol.
308.94K
Volume
159.24K
Dividend
0.18%
Quarterly dividend
₹0.75
Ex dividend date
Aug 14, 2025
P/E ratio
33.98
52-wk high
₹1,830.00
52-wk low
₹1,013.40
EPS
₹48.77
No. of employees
7K
News stories
From sources across the web
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees6.73K
FoundedApr 16, 1981
Headquarters-
SectorPharmaceutical industry
Websiteemcure.com
Last report
May 5, 2026
Fiscal Period
Q4 2026
EPS / Est. (INR)
₹14.70 / ₹14.70
+0.00%beat
Revenue / Est. (INR)
24.74B / 24.20B
+2.22%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
21.01B
22.70B
23.63B
24.74B
Cost of goods sold
8.02B
8.90B
9.62B
10.03B
Cost of revenue
8.02B
8.90B
9.62B
10.03B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.93B
3.85B
3.87B
3.87B
Operating expense
9.94B
10.46B
10.46B
10.87B
Total operating expenses
17.96B
19.35B
20.08B
20.90B
Operating income
3.04B
3.34B
3.55B
3.83B
Other non operating income
36.96M
31.23M
18.53M
-
EBT including unusual items
2.91B
3.41B
3.14B
3.41B
EBT excluding unusual items
2.94B
3.41B
3.52B
3.74B
Income tax expense
759.65M
900.47M
824.22M
974.40M
Effective tax rate
26.13%
26.37%
26.27%
28.56%
Other operating expenses
5.01B
5.57B
5.54B
5.94B
Net income
2.07B
2.43B
2.31B
2.43B
Net profit margin
9.85%
10.73%
9.75%
9.84%
Earnings per share
11.06
12.85
13.67
14.70
Interest and investment income
-
-
-
-
Interest expense
-267.55M
-325.42M
-379.75M
-464.01M
Net interest expenses
-267.55M
-325.42M
-379.75M
-464.01M
Depreciation and amortization charges
994.56M
1.05B
1.05B
1.06B
EBITDA
3.86B
4.37B
4.37B
4.87B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer